[1]
|
Nalysnyk, L., Rotella, P., Simeone, J.C., Hamed, A. and Weinreb, N. (2017) Gaucher Disease Epidemiology and Natural History: A Comprehensive Review of the Literature. Hematology, 22, 65-73.
https://doi.org/10.1080/10245332.2016.1240391
|
[2]
|
Zion, Y.C., Pappadopulos, E., Wajnrajch, M., et al. (2016) Re-Thinking Fatigue in Gaucher Disease. Orphanet Journal of Rare Diseases, 29, 1-7.
|
[3]
|
Masi, L. and Brandi, M.L. (2015) Gaucher Disease: The Role of the Specialist on Metabolic Bone Diseases. Clinical Cases in Mineral and Bone Metabolism, 12, 165-169. https://doi.org/10.11138/ccmbm/2015.12.2.165
|
[4]
|
Casirati, G., Baldini, M., Ulivieri, F.M., et al. (2018) Skeletal Involvement in Type 1 Gaucher Disease: Not Just Bone Mineral Density. Blood Cells, Molecules, and Diseases, 68, 148-152. https://doi.org/10.1016/j.bcmd.2017.06.003
|
[5]
|
Marcucci, G., Zimran, A., Bembi, B., et al. (2014) Gaucher Disease and Bone Manifestations. Calcified Tissue International, 95, 477-494. https://doi.org/10.1007/s00223-014-9923-y
|
[6]
|
Biegstraaten, M., Cox, T.M., Belmatoug, N., et al. (2016) Management Goals for Type 1 Gaucher Disease: An Expert Consensus Document from the European Working Group on Gaucher Disease. Blood Cells, Molecules, and Diseases, 68, 203-208. https://doi.org/10.1016/j.bcmd.2016.10.008
|
[7]
|
Masi, L. and Brandi, M.L. (2015) Gaucher Disease: The Role of the Specialist on Metabolic Bone Diseases. Clinical Cases in Mineral and Bone Metabolism, 12, 165-169. https://doi.org/10.11138/ccmbm/2015.12.2.165
|
[8]
|
Kaluzna, M., Trzeciak, I., Ziemnicka, K., Machaczka, M. and Ruchała, M. (2019) Endocrine and Metabolic Disorders in Patients with Gaucher Disease Type 1: A Review. Orphanet Journal of Rare Diseases, 14, Article No. 275.
https://doi.org/10.1186/s13023-019-1211-5
|
[9]
|
Yang, A.C., Bier, L., Overbey, J.R., et al. (2017) Early Manifestations of Type 1 Gaucher Disease in Presymptomatic Children Diagnosed after Parental Carrier Screening. Genetics in Medicine, 19, 652-658.
https://doi.org/10.1038/gim.2016.159
|
[10]
|
Giraldo, P., Pérez-López, J., Núňez, R., et al. (2016) Patients with Type 1 Gaucher Disease in Spain: A Cross-Sectional Evaluation of Health Status. Blood Cells, Molecules, and Diseases, 56, 23-30.
https://doi.org/10.1016/j.bcmd.2015.10.001
|
[11]
|
Hughes, D., Mikosch, P., Belmatoug, N., et al. (2019) Gaucher Disease in Bone: From Pathophysiology to Practice. Journal of Bone and Mineral Research, 34, 996-1013. https://doi.org/10.1002/jbmr.3734
|
[12]
|
Orenstein, M., Barbouth, D., Bodamer, O.A. and Weinreb, N.J. (2014) Patients with Type 1 Gaucher Disease in South Florida, USA; Demographics, Genotypes, Disease Severity and Treatment Outcomes. Orphanet Journal of Rare Diseases, 9, Article No. 45. https://doi.org/10.1186/1750-1172-9-45
|
[13]
|
张博健, 乔海泉. 戈谢病的外科研究进展[J]. 腹部外科, 2019, 32(2): 144-147.
|
[14]
|
Motta, I., Filocamo, M., Poggiali, E., et al. (2016) A Multicentre Observational Study for Early Diagnosis of Gaucher Disease in Patients with Splenomegaly and/or Thrombocytopenia. European Journal of Haematology, 96, 352-359.
https://doi.org/10.1111/ejh.12596
|
[15]
|
Essabar L, Meskini T, Lamalmi N, et al. (2015) Gaucher’s Disease: Report of 11 Cases with Review of Literature. Pan Afr Med J., 20, 18. https://doi.org/10.11604/pamj.2015.20.18.4112
|
[16]
|
Van Dussen, L., Biegstraaten, M., Dijkgraaf, M.G.W. and Hollak, C.E.M. (2014) Modelling Gaucher Disease Progression: Long Term Enzyme Replacement Therapy Reduces the Incidence of Splenectomy and Bone Complications. Orphanet Journal of Rare Diseases, 9, Article No. 112. https://doi.org/10.1186/s13023-014-0112-x
|
[17]
|
Revel-Vilk, S., Szer, J., Mehta, A., et al. (2018) How We Manage Gaucher Disease in the Era of Choices. British Journal of Haematology, 182, 467-480. https://doi.org/10.1111/bjh.15402
|
[18]
|
中华医学会儿科学分会遗传代谢内分泌学组, 中华医学会儿科学分会血液学组, 中华医学会血液学分会红细胞疾病(贫血)学组. 中国戈谢病诊治专家共识[J]. 中华儿科杂志, 2015, 53(4): 256-261.
|
[19]
|
El-Beshlawy, A., Tylki-Szymanska, A., Vellodi, A., et al. (2017) Long-Term Hematological, Visceral, and Growth Outcomes in Children with Gaucher Disease Type 3 Treated with Imiglucerase in the International Collaborative Gaucher Group Gaucher Registry. Molecular Genetics and Metabolism, 120, 47-56.
https://doi.org/10.1016/j.ymgme.2016.12.001
|
[20]
|
中国成人戈谢病诊治专家共识(2020) [J]. 中华医学杂志, 2020, 100(24): 1841-1849.
|
[21]
|
Zimmermann, A., Popp, R.A., Al-Khzouz, C., et al. (2016) Cholelithia-sis in Patients with Gaucher Disease Type 1: Risk Factors and the Role of ABCG5/ABCG8 Gene Variants. Journal of Gastrointestinal and Liver Diseases, 25, 447-455. https://doi.org/10.15403/jgld.2014.1121.254.zim
|
[22]
|
韩冰, 陈苗, 杨辰. 戈谢病多学科诊疗专家共识(2020) [J]. 协和医学杂志, 2020, 11(6): 682-697.
|
[23]
|
Clarke, L.A. and Hollak, C.E.M. (2015) The Clinical Spectrum and Pathophysiology of Skeletal Complications in Lysosomal Storage Disorders. Best Practice & Research Clinical Endocrinology & Metabolism, 29, 219-235.
https://doi.org/10.1016/j.beem.2014.08.010
|
[24]
|
莫志强, 王大勇, 李小松, 等. 脾切除及保留副脾治疗儿童戈谢病的疗效观察[J]. 中华小儿外科杂志, 2016, 37(7): 537-540.
|